The U.S. Food and Drug Administration (FDA) will convene an advisory panel this fall to examine the rise of artificial intelligence (AI) tools designed for mental health support.
The FDA’s Digital Health Advisory Committee (DHAC) will meet on November 6 to explore how these technologies could help close the nation’s growing gap in access to mental health services. The panel will also weigh the potential risks of relying on AI-driven care.
Growing Role of AI in Mental Health
In recent years, there has been rapid growth in digital mental health products, ranging from chatbots to virtual therapy platforms. Advocates say these tools could expand access, offer more timely support, and make mental health care more scalable.
But experts caution that regulators must carefully evaluate whether such devices are truly safe and effective. Unlike traditional medical devices, AI tools can learn and adapt over time, raising unique regulatory challenges.
FDA’s Next Steps
According to an FDA briefing document, the November meeting will help establish priorities for oversight and highlight areas where further guidance is needed. The DHAC is tasked with advising the agency on regulatory issues related to:
- Artificial intelligence and machine learning (AI/ML)
- Remote patient monitoring
- Digital therapeutics
- Software used in medical devices
The FDA has also been experimenting with AI in its own review processes, signaling its commitment to understanding the technology from multiple angles.
Public Input Invited
Ahead of the meeting, the agency has opened a public docket for comments. Background materials and discussion topics will be made available on the FDA’s website at least two business days before the session.
YOU MAY ALSO LIKE
AI and Mental Health: Why Experts Say Chatbots Aren’t Enough
What Regular Energy Drink Use Does to Your Mental Health
Smartwatches May Help Detect PTSD From Media Exposure After Trauma
